Piermont Capital Management’s Charles River Laboratories CRL Stock Holding History

Piermont Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-14,919	Closed	-$1.23M	–	254
2016 Q2	$1.23M	Buy	14,919 +7,239	+94%	+$596K	0.32%	116
2016 Q1	$583K	Buy	7,680 +280	+4%	+$20.7K	0.19%	130
2015 Q4	$595K	Buy	7,400 +1,000	+16%	+$72.1K	0.19%	125
2015 Q3	$407K	Hold	6,400	–	–	0.13%	170
2015 Q2	$450K	Buy	+6,400	New	+$474K	0.14%	179
2015 Q1	–	Sell	-44,700	Closed	-$2.85M	–	239
2014 Q4	$2.85M	Sell	44,700 -570	-1%	-$35.7K	1.01%	31
2014 Q3	$2.7M	Sell	45,270 -3,670	-7%	-$210K	1.05%	23
2014 Q2	$2.62M	Buy	48,940 +7,740	+19%	+$425K	1.02%	39
2014 Q1	$2.49M	Buy	41,200 +920	+2%	+$53.6K	1.2%	11
2013 Q4	$2.14M	Buy	+40,280	New	+$2.02M	1.07%	24

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Piermont Capital Management's CRL Position: Q3 2016 in Review

Piermont Capital Management sold out of Charles River Laboratories (CRL) in Q3 2016, closing a stake of 14,919 shares — an estimated $1.23M sold.

Piermont Capital Management first reported a position in CRL in Q4 2013 and held it in 10 quarters. The position peaked at $2.85M in Q4 2014. 284 funds tracked by Wall St. Rank hold CRL as of Q3 2016.

Piermont Capital Management reported no remaining Charles River Laboratories position as of Q3 2016 after selling out during the quarter.
Piermont Capital Management sold 14,919 Charles River Laboratories shares in Q3 2016, an estimated $1.23M.
Piermont Capital Management first reported a position in Charles River Laboratories in Q4 2013 and held it in 10 quarters.
Piermont Capital Management's Charles River Laboratories position peaked at $2.85M in Q4 2014.
284 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2016.

Based on Piermont Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.